Gastrointestinale Nebenwirkungen durch nichtsteroidale Antirheumatika (NSAR)

Bresalier RS, Sandler RS, Quan H et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352(11): 1092–1102

Bolten WW, Lang B, Wagner AV, Krobot KJ (1999) Consequences and costs of NSAID-induced gastropathy in Germany. Akt Rheumatol 24: 127–134. Available from http://www.thieme.de/rheuma/aktuelles/aktuell-en.pdf

Bolten WW (2005) Der steinige Weg zu besser verträglichen Antirheumatika. DMW 130(33): 1897

Bolten WW (2006) Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs. Ann Rheum Dis 65(1): 7–13

Cryer B, Kimmey MB (1998) Gastrointestinal side effects of nonsteroidal anti-inflammatory drugs. Am J Med 105(1B): 20S–30S

Hooper L, Brown TJ, Elliott R et al. (2004) The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 329(7472): 948–950

Kearney PM, Baigent C, Godwin J et al. (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332(7553): 1302–1308

Laine L, Connors LG, Reicin A et al. (2003) Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 124(2): 288–292

Singh G, Triadafilopoulos G (1999) Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 26 [Suppl 56]:18–24

Talley NJ, Evans JM, Fleming KC et al. (1995) Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig Dis Sci 40(6):1345–1350